John Mascarenhas, MD, and Joe Scandura, MD, PhD, discuss recent advances in the treatment of polycythemia vera (PV) and the impact on clinical practice.
August 11th 2023
Joe Scandura, MD, PhD, reviews how he approaches risk assessment in patients with polycythemia vera and how risk score helps to determine treatment.
Dr Joe Scandura discusses how he considers risk of disease progression when during therapeutic decision making for a patient with polycythemia vera.
August 18th 2023
John Mascarenhas, MD, and Joe Scandura, MD, PhD, detail the typical presentation of a patient with polycythemia vera in their clinical practices.
Experts explain the critical importance of obtaining bone marrow biopsies for accurately diagnosing polycythemia vera.
August 25th 2023
Key opinion leaders discuss their treatment targets for low- and high-risk patients with polycythemia vera.
Joe Scandura, MD, PhD, explains how he considers individual symptom burden when deciding on a treatment regimen for a patient with polycythemia vera.
September 1st 2023
Drs John Mascarenhas and Joe Scandura review the toxicities seen with the non-specific chemotherapeutic agent hydroxyurea in patients with polycythemia vera.
Joe Scandura, MD, PhD, summarizes the toxicity profile of interferon therapy in patients with polycythemia vera.
September 8th 2023
Experts review critical trial data in the treatment of patients with polycythemia vera.
Drs Joe Scandura and John Mascarenhas discuss their treatment approaches for high-risk patients with polycythemia vera.